EOCNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Galmed Pharmaceuticals Ltd.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 31, 2026
$2.85−0.00 (-0.00%)
Close on Oct 19, 2026
- Market cap
- $2.71M
- P/E (TTM)
- 0.1
- Dividend yield
- –
Galmed Pharmaceuticals statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Galmed Pharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $2.85M | $164.85M |
| Enterprise Value | -$5.91M | $87.06M |
| PB Ratio | 0.22 | 2.03 |
| P/TBV Ratio | 0.26 | 2.31 |
Income (trailing twelve months)
| Measure | Galmed Pharmaceuticals | Industry median |
|---|---|---|
| Net Income | -$11.34M | -$22.46M |
Returns
| Measure | Galmed Pharmaceuticals | Industry median |
|---|---|---|
| Return on Equity (ROE) | -68.2% | -53.1% |
| Return on Assets (ROA) | -55.0% | -41.0% |
Growth
| Measure | Galmed Pharmaceuticals | Industry median |
|---|---|---|
| EPS Growth (3Y CAGR) | -73.5% | -0.17% |
Balance sheet
| Measure | Galmed Pharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $8.77M | $62.42M |
| Net Cash (Debt) | $8.77M | $15.68M |
| Net Cash Per Share | $8.75 | $0.66 |
| Equity (Book Value) | $12.74M | $48.79M |
| Book Value Per Share | $12.72 | $1.36 |
| Tangible Book Value | $10.97M | $23.06M |
| Working Capital | $8.90M | $75.77M |
Financial position
| Measure | Galmed Pharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 4.16 | 3.30 |
| Quick Ratio | 3.12 | 2.39 |
Efficiency
| Measure | Galmed Pharmaceuticals | Industry median |
|---|---|---|
| Profits Per Employee | -$1.89M | -$703.34K |
| Employee Count | 6 | 74 |
Dividends and yields
| Measure | Galmed Pharmaceuticals | Industry median |
|---|---|---|
| Earnings Yield | -397.4% | -22.7% |
Shares
| Measure | Galmed Pharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 1,001,390 | 58,179,650 |
| Float | 823,251 | 49,173,100 |
| Shares Held by Insiders | 17.8% | 11.6% |
Scores
| Measure | Galmed Pharmaceuticals | Industry median |
|---|---|---|
| Altman Z-Score | -15.60 | -0.24 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from Galmed Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.